symbol,statement_type,period_end,line_item,value
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,40857094.404443
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.207532
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,592609000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items,196871000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,196871000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,553611000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,81310000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,964380000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,EBITDA,789480000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,EBIT,708170000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Interest Income,-9580000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Interest Expense,9580000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Interest Income,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Normalized Income,397597094.404443
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,553611000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Total Expenses,2257760000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Basic Average Shares,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Diluted EPS,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Basic EPS,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,553611000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,553611000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Income,553611000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,553610000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,553610000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Tax Provision,144980000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Pretax Income,698590000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,81900000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Special Income Charges,196871000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Other Special Charges,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Write Off,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-9580000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,9580000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Operating Income,429400000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Operating Expense,1293380000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,502740000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,81310000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,81310000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Selling General And Administration,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Gross Profit,1722780000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,964380000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Total Revenue,2687160000.0
JAGSNPHARM.NS,income,2025-03-31 00:00:00,Operating Revenue,2687160000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.247949
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,323460000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,16630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,799770000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,EBITDA,323460000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,EBIT,306830000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Interest Income,-8140000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Interest Expense,8140000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Interest Income,85920000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Normalized Income,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Total Expenses,1872980000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,9130000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,66262537.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Basic Average Shares,66067647.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Diluted EPS,3.39
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Basic EPS,3.4
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Income,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,224630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Tax Provision,74060000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Pretax Income,298690000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,92790000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Other Special Charges,
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Write Off,
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-8140000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,370000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,8140000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,85920000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Operating Income,214040000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Operating Expense,1073210000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,435670000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,16630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,16630000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Selling General And Administration,201410000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,163360000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,38050000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,9130000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Gross Profit,1287250000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,799770000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Total Revenue,2087020000.0
JAGSNPHARM.NS,income,2024-03-31 00:00:00,Operating Revenue,2087020000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-6928129.74029
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.232332
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Normalized EBITDA,392130000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items,-29520000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-29820000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,11750000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,925140000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,EBITDA,362610000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,EBIT,350860000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Interest Income,30150000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Interest Expense,2780000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Interest Income,34280000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Normalized Income,290401870.25971
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Total Expenses,2023840000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,18310000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Diluted Average Shares,65495000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Basic Average Shares,65495000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Diluted EPS,4.08
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Basic EPS,4.08
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Income,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,267210000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Tax Provision,80870000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Pretax Income,348080000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,4460000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Special Income Charges,-31300000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Other Special Charges,31000000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Write Off,2620000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,30150000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,1350000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,2780000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,34280000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Operating Income,343300000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Operating Expense,1098700000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Other Operating Expenses,185640000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,11750000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,11750000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Selling General And Administration,234660000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,178730000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,General And Administrative Expense,55930000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,18310000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Gross Profit,1442000000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Cost Of Revenue,925140000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Total Revenue,2367140000.0
JAGSNPHARM.NS,income,2023-03-31 00:00:00,Operating Revenue,2367140000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,-1382497.93559
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.292283
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Normalized EBITDA,289020000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items,-4730000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-4730000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,15260000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,892820000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,EBITDA,284290000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,EBIT,269030000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Interest Income,12610000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Interest Expense,2610000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Interest Income,15460000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Normalized Income,191897502.06441
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Total Expenses,1930390000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,24770000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Diluted Average Shares,65495000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Basic Average Shares,65495000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Diluted EPS,2.88
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Basic EPS,2.88
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Income,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,188550000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Tax Provision,77870000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Pretax Income,266420000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,1740000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Special Income Charges,430000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Other Special Charges,-850000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Write Off,420000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,12610000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,240000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,2610000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,15460000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Operating Income,245450000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Operating Expense,1037570000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Other Operating Expenses,180270000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,15260000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,15260000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Selling General And Administration,240520000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,138790000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,General And Administrative Expense,101730000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,24770000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Gross Profit,1283020000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Cost Of Revenue,892820000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Total Revenue,2175840000.0
JAGSNPHARM.NS,income,2022-03-31 00:00:00,Operating Revenue,2175840000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,EBITDA,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,EBIT,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Interest Income,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Interest Expense,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Interest Income,29924000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Normalized Income,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Total Expenses,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,22687000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Diluted Average Shares,65495000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Basic Average Shares,65495000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Diluted EPS,2.604
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Basic EPS,2.604
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Income,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Tax Provision,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Pretax Income,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Special Income Charges,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Other Special Charges,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Write Off,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,860000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,29924000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Operating Income,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Operating Expense,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Selling General And Administration,172624000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,129901000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,General And Administrative Expense,42723000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,22687000.0
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Gross Profit,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Total Revenue,
JAGSNPHARM.NS,income,2021-03-31 00:00:00,Operating Revenue,
